Meeting
2022 ASCO Annual Meeting
Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.
Authors
Malin Hultcrantz
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Malin Hultcrantz , David Kleinman , Pavandeep Ghataorhe , Astrid McKeown , Wei He , Thomas Ling , Roxanne C. Jewell , Julie Byrne , Laurie Eliason , Emma Catherine Scott , Joanna Opalinska
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT05064358
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8073)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8073
Abstract #
TPS8073
Poster Bd #
493b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.
First Author: Wenfeng Fang
Poster
2021 ASCO Annual Meeting
Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).
First Author: Evangelos Terpos
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.
First Author: Xavier Leleu
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld